Value of follow-up diagnostic radioiodine scans in differentiated thyroid cancer

Value of follow-up diagnostic radioiodine scans in differentiated thyroid cancer

Background: The most important part of the follow-up of differentiated thyroid carcinoma (DTC) is the measurement of serum thyroglobulin (Tg). An increase of Tg levels indicates likely tumor recurrence. According to the guidelines of the European Society of Medical Oncology (ESMO), the follow-up sho...

Full description

Bibliographic Details
Main Authors:	Teresa Kraus, Natalia Shengelia-de Lange, Holger Einspieler, Marcus Hacker, Alexander Haug, Elisabeth Kretschmer-Chott, Georgios Karanikas
Format:	Article
Language:	English
Published:	Bioscientifica 2024-04-01
Series:	Endocrine Connections
Subjects:	thyroid cance thyroglobulin follow-up diagnostic radioiodine whole-body scan
Online Access:	https://ec.bioscientifica.com/view/journals/ec/13/5/EC-24-0007.xml

Similar Items

A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer
by: Chao Meng, et al.
Published: (2023-02-01)

Guidelines for radioiodine therapy in differentiated thyroid cancer and post-therapeutic follow-up
by: A. Yu. Shurinov, et al.
Published: (2024-06-01)

Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma
by: Elisa Minaldi, et al.
Published: (2023-01-01)

Distinguishing Patients With Distant Metastatic Differentiated Thyroid Cancer Who Biochemically Benefit From Next Radioiodine Treatment
by: Ri Sa, et al.
Published: (2020-11-01)

Successful pregnancy without disease progression of radioiodine refractory papillary thyroid carcinoma: a case report
by: Yuchen Jin, et al.
Published: (2017-11-01)

Prognostic factors in children and adolescents with differentiated thyroid cancer treated with total thyroidectomy and radioiodine therapy: a retrospective two-center study from China
by: Congcong Wang, et al.
Published: (2024-07-01)

Prognostic factors for postoperative papillary thyroid cancer with unexplained elevated Tg: A retrospective study
by: Chenghui Lu, et al.
Published: (2024-03-01)

Added Value of Postoperative Radioiodine Scan for Staging and Risk Stratification in Papillary Thyroid Microcarcinoma
by: Tawika Kaewchur, et al.
Published: (2021-04-01)

Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients
by: Carla Gambale, et al.
Published: (2023-10-01)

Retrospective Analysis of the Development of Human Thyroglobulin during Pregnancy in Patients with Treated Non-Recurrent Differentiated Thyroid Cancer
by: Justus Baumgarten, et al.
Published: (2022-05-01)

Is 131I ablation necessary for patients with low-risk papillary thyroid carcinoma and slightly elevated stimulated thyroglobulin after thyroidectomy?
by: Pedro Weslley Rosario, et al.

CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY
by: P. O. Rumyantsev, et al.
Published: (2015-04-01)

Development of a predictive nomogram for intermediate-risk differentiated thyroid cancer patients after fixed 3.7GBq (100mCi) radioiodine remnant ablation
by: Lu Lu, et al.
Published: (2024-05-01)

Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers
by: Abdul Rehman Syed, et al.
Published: (2024-05-01)

Evaluation of Discordance in Differentiated Thyroid Cancer Patients with Negative Radioiodine Scans and Positive Thyroglobulin Values at the Ablation Outcome Control
by: Zeynep Gözde Özkan, et al.
Published: (2012-03-01)

Value of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in staging of patients with differentiated thyroid cancer after thyroidectomy during the first course of radioiodine therapy
by: T. M. Geliashvili, et al.
Published: (2021-01-01)

Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
by: Aleksandra Kukulska, et al.
Published: (2020-08-01)

Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial
by: Maaike Dotinga, et al.
Published: (2022-12-01)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
by: Urbano Anido Herranz
Published: (2022-10-01)

A Novel Reagent for Radioiodine Labeling of New Chemical Entities (NCEs) and Biomolecules
by: Krishan Kumar, et al.
Published: (2021-07-01)

Clinical utility of 18F-FDG PET/CT in the follow-up of a large cohort of patients with high-risk differentiated thyroid carcinoma
by: Ji H. Yang, et al.
Published: (2017-09-01)

Occurrence of symptomatic meningioma as a second neoplasm in patients with differentiated thyroid cancer treated with radioiodine
by: Nishikant Avinash Damle, et al.
Published: (2012-01-01)

Uptake and effect of radioiodine exposure on SKBR-3 cell lines
by: Miftah Irramah, et al.
Published: (2019-12-01)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
by: Genpeng Li, et al.
Published: (2018-11-01)

Radioiodine treatment in female survivors of pediatric differentiated thyroid carcinoma does not affect future pregnancy rates
by: Marise Codeco de Andrade Barreto, et al.
Published: (2024-10-01)

Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration
by: Yu-qing Sun, et al.
Published: (2022-11-01)

The use of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in patients with differentiated thyroid cancer after initial treatment
by: T. M. Geliashvili, et al.
Published: (2017-04-01)

Sudden Development of Subcutaneous Nodules Shortly after Radioiodine Treatment for Thyroid Cancer Caused by Self-Limiting Sarcoidosis
by: Wael Zaher, et al.
Published: (2020-05-01)

TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer
by: Nianting Ju, et al.
Published: (2023-06-01)

Concomitant lithium increases radioiodine uptake and absorbed doses per administered activity in graves’ disease: comparison of conventional versus lithium-augmented radioiodine therapy
by: Fadi Khreish, et al.
Published: (2024-04-01)

Radiation Exposure Levels in Relatives of Patients after Radioiodine Therapy
by: Bererhi H, et al.
Published: (2000-10-01)

Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer
by: Massimiliano Pacilio, et al.
Published: (2022-07-01)

Performance tests of a portable thyroid radioiodine meter
by: Zeshu Li, et al.
Published: (2024-03-01)

Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study
by: Jinyan Chai, et al.
Published: (2022-06-01)

2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?
by: Furio Pacini, et al.
Published: (2023-01-01)

A rare case of laryngotracheal chondrosarcoma in a patient with past history of radioiodine therapy for thyroid cancer
by: Gholamreza Mohajeri, et al.
Published: (2013-01-01)

Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma
by: S.M. Coelho, et al.
Published: (2011-01-01)

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
by: Dario Tumino, et al.
Published: (2017-11-01)

Progress on Targeted Therapy of Radioiodine-refractory Differentiated Thyroid Cancer
by: TENG Lisong, et al.
Published: (2023-05-01)